TAK
Takeda PharmaceuticalDNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
Bull case: Successful clinical readouts, clearer post-quarter guidance, and tangible cost-synergy realization drive re-rating toward the analyst high (19.5). Stronger-than-expected launch execution or an accretive licensing/M&A outcome would add incremental upside.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Failure to deliver integration synergies or cost savings
Momentum
27
Value
64
Sentiment
46
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $17.00 · Bull $19.50 · Bear $14.87
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-30 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $18.69
Why
Momentum27 · Δ7d -14.1
Value64 · Δ7d -0.1
Sentiment46 · Δ7d -6.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
27
26% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
+8.2
Value
64
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.5
Sentiment
46
34% active weight
Current posture
7d trendSoftening
Δ7d
-6.5
Δ21d
-10.5
Why this grade
Composite grade D. Momentum 27.5 / Value 64.2 / Sentiment 46.4
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$54.39B
Beta
0.05
Shares Out
3.18B
P/E (TTM)
226.9
P/S (TTM)
1.77
P/FCF (TTM)
12.72
Rev YoY
+0.9%
EPS YoY
+246.7%
Gross Margin
+53.5%
Op Margin
+5.6%
Net Debt
$30.68B
Current Ratio
1.09
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology